Wu, A. et al. Smartphone apps for depression and anxiety: a systematic review and meta-analysis of techniques to increase engagement. npj Digit Med. 4, 20 (2021).
Google Scholar
Linardon, J. et al. Current evidence on the efficacy of mental health smartphone apps for symptoms of depression and anxiety. A meta-analysis of 176 randomized controlled trials. World Psychiatry 23, 139–149 (2024).
Google Scholar
Sit, H. F. et al. Digital mental health: a potential opportunity to improve health equity in China. Lancet Public Health 9, e1136–e1141 (2024).
Google Scholar
Masanneck, L. & Stern, A. D. Tracing digital therapeutics research across medical specialties: evidence from ClinicalTrials.gov. Clin. Pharma Therapeutics 116, 177–185 (2024).
Google Scholar
Sun, S., Simonsson, O., McGarvey, S., Torous, J. & Goldberg, S. B. Mobile phone interventions to improve health outcomes among patients with chronic diseases: an umbrella review and evidence synthesis from 34 meta-analyses. Lancet Digit Health 6, e857–e870 (2024).
Google Scholar
Cox D The Guardian. ‘They thought they were doing good but it made people worse’: why mental health apps are under scrutiny. (2024).
Simon, D. A., Shachar, C. & Cohen, I. G. Skating the line between general wellness products and regulated devices: strategies and implications. J. Law Biosci. 9, lsac015 (2022).
Google Scholar
Simon, D. A., Shachar, C. & Cohen, I. G. At-home diagnostics and diagnostic excellence: devices vs general wellness products. JAMA 327, 523 (2022).
Google Scholar
Wang, C., Lee, C. & Shin, H. Digital therapeutics from bench to bedside. npj Digit Med. 6, 38 (2023).
Google Scholar
U.S. Food & Drug Administration. Device Software Functions Including Mobile Medical Applications. September 2022.
U.S. Food & Drug Administration. CFR – Code of Federal Regulations Title 21. 08.24. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5801
U.S. Food & Drug Administration. Class II Special Controls Documents. June 2022.
U.S. Food & Drug Administration. De Novo Classification Request. April 2022.
U.S. Food & Drug Administration. 510 Premarket Notification. March 30, 2024.
Aboy, M., Crespo, C. & Stern, A. Beyond the 510(k): The regulation of novel moderate-risk medical devices, intellectual property considerations, and innovation incentives in the FDA’s De Novo pathway. npj Digit Med. 7, 29 (2024).
Google Scholar
Watson, A., Chapman, R., Shafai, G. & Maricich, Y. A. FDA regulations and prescription digital therapeutics: Evolving with the technologies they regulate. Front Digit Health 5, 1086219 (2023).
Google Scholar
Kadakia, K. T., Rathi, V. K., Dhruva, S. S., Ross, J. S. & Krumholz, H. M. Modernizing Medical Device Regulation: Challenges and Opportunities for the 510(k) Clearance Process. Ann. Intern Med. 177, 1558–1565 (2024).
Google Scholar
Johnston, J. L., Dhruva, S. S., Ross, J. S. & Rathi, V. K. Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019. JAMA Intern Med. 180, 1701 (2020).
Google Scholar
Rathi, V. K. & Ross, J. S. Modernizing the FDA’s 510(k) Pathway. N. Engl. J. Med. 381, 1891–1893 (2019).
Google Scholar
U.S. Food & Drug Administration. Device Classification Under Section 513(f)(2)(De Novo). January 2025.
U.S. Food & Drug Administration. DE NOVO CLASSIFICATION REQUEST FOR RESET. May 2016.
U.S. Food & Drug Administration. De novo classification request for EndeavorRx. April 2020.
U.S. Food & Drug Administration. De novo classification request for EASEVRx. March 2021.
Maricich, Y. A. et al. Safety and efficacy of a prescription digital therapeutic as an adjunct to buprenorphine for treatment of opioid use disorder. Curr. Med. Res. Opin. 37, 167–173 (2021).
Google Scholar
Christensen, H. et al. Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight Study): a randomised controlled trial. Lancet Psychiatry 3, 333–341 (2016).
Google Scholar
U.S. Food & Drug Administration. Rejoyn FDA authorization. March 30, 2024.
Rothman, B. et al. A digital therapeutic (CT-152) as adjunct to antidepressant medication: A phase 3 randomized controlled trial (the Mirai study). J. Affect. Disord. 388, 119409 (2025).
Google Scholar
U.S. Food & Drug Administration. Sleepio FDA authorization. August 5, 2024.
U.S. Food & Drug Administration. Daylight FDA authorization. August 30, 2024.
U.S. Food & Drug Administration. MamaLift Plus FDA authorization. April 22, 2024.
Blease, C. Out of control: how to design digital placebos. Curr. Treat. Options Psych. 10, 109–118 (2023).
Google Scholar
Morrison, L. G. et al. Comparing usage of a web and app stress management intervention: An observational study. Internet Interventions 12, 74–82 (2018).
Google Scholar
Ripley, E., Macrina, F., Markowitz, M. & Gennings, C. Who’s Doing the Math? Are We Really Compensating Research Participants? J. Empir. Res. Hum. Res. Ethics 5, 57–65 (2010).
Google Scholar
Swanson, D. M. & Betensky, R. A. Research participant compensation: A matter of statistical inference as well as ethics. Contemp. Clin. Trials 45, 265–269 (2015).
Google Scholar
The Institute for Clinical and Economic Review (ICER). ICER Publishes Evidence Report on Digital Therapeutics for Opioid Use Disorder. November 2020.
Institute of Data. Evidence Rating Matrix. 2023.
Pokhrel, P., Rath, S., Aggarwal, R., Shah, S. T. & Ahmadi, L. Enhancing mental wellness: A reflection on Rejoyn app’s FDA approval for depression management. Asian J. Psychiatry 99, 104147 (2024).
Google Scholar
Richmond L. M. Rejoyn: First App Cleared by FDA for Depression; Cost, Efficacy Unclear. PN. 59:appi.pn.2024.06.6.15. 2024.
Zagorski N. Jury Still Out on Digital Therapies for ADHD. January, 2024.
UnitedHealthcare. Prior Authorization/Medical Necessity – Digital Applications. January 2024.
Jacoby, V. L., Subak, L. & Waetjen, L. E. The FDA and the Vaginal Mesh Controversy—Further Impetus to Change the 510(k) Pathway for Medical Device Approval. JAMA Intern. Med. 176, 277 (2016).
Google Scholar
Ardaugh, B. M., Graves, S. E. & Redberg, R. F. The 510(k) Ancestry of a Metal-on-Metal Hip Implant. N. Engl. J. Med. 368, 97–100 (2013).
Google Scholar
Prentice, C. et al. Methods for evaluating the efficacy and effectiveness of direct-to-consumer mobile health apps: a scoping review. BMC Digit Health 2, 31 (2024).
Google Scholar
Torous, J., Stern, A. D. & Bourgeois, F. T. Regulatory considerations to keep pace with innovation in digital health products. npj Digit Med 5, 121 (2022).
Google Scholar
U.S. Food & Drug Administration. Digital Health Software Precertification (Pre-Cert) Pilot Program. September 2022.
Ferdous A. F. FDA acknowledges shortcomings of Pre-Cert pilot in report. Regulatory Focus. October 2022.
Schmidt, L., Pawlitzki, M., Renard, B. Y., Meuth, S. G. & Masanneck, L. The three-year evolution of Germany’s Digital Therapeutics reimbursement program and its path forward. npj Digit Med. 7, 139 (2024).
Google Scholar
Gerke, S., Stern, A. D. & Minssen, T. Germany’s digital health reforms in the COVID-19 era: lessons and opportunities for other countries. npj Digit Med. 3, 94 (2020).
Google Scholar
U. S. Food & Drug Administration. Deciding When to Submit a 510(k) for a Change to an Existing Device. October 25, 2017.
Murphy, S. M. et al. Cost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial. Drug Alcohol Depend. 161, 119–126 (2016).
Google Scholar
Ritterband, L. M. et al. Effect of a Web-Based Cognitive Behavior Therapy for Insomnia Intervention With 1-Year Follow-up: A Randomized Clinical Trial. JAMA Psychiatry 74, 68 (2017).
Google Scholar
Kollins, S. H. et al. A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. Lancet Digital Health 2, e168–e178 (2020).
Google Scholar
U.S. Food & Drug Administration. EndeavorRx v3.0 FDA authorization. December 13, 2023.
U.S. Food & Drug Administration. EndeavorOTC FDA authorization. June 14, 2024.
Garcia, L. et al. Durability of the Treatment Effects of an 8-Week Self-administered Home-Based Virtual Reality Program for Chronic Low Back Pain: 6-Month Follow-up Study of a Randomized Clinical Trial. J. Med Internet Res. 24, e37480 (2022).
Google Scholar
Čeko, M., Baeuerle, T., Webster, L., Wager, T. D. & Lumley, M. A. The effects of virtual reality neuroscience-based therapy on clinical and neuroimaging outcomes in patients with chronic back pain: a randomized clinical trial. Pain 165, 1860–1874 (2024).
Google Scholar
U.S. Food & Drug Administration. RelieVRx FDA authorization. https://www.accessdata.fda.gov/cdrh_docs/pdf24/K243417.pdf,
U.S. Food & Drug Administration. 510(k) Summary For The Intercure Ltd. RESPeRATE. Published online January 2002.
Meuret, A. E., Wilhelm, F. H., Ritz, T. & Roth, W. T. Feedback of end-tidal pCO2 as a therapeutic approach for panic disorder. J. Psychiatr. Res. 42, 560–568 (2008).
Google Scholar
Meuret, A. E., Rosenfield, D., Seidel, A., Bhaskara, L. & Hofmann, S. G. Respiratory and cognitive mediators of treatment change in panic disorder: Evidence for intervention specificity. J. Consulting Clin. Psychol. 78, 691–704 (2010).
Google Scholar
ClinicalTrials.gov. Investigation of the Freespira Breathing System in the Treatment of Post Traumatic Stress Disorder (PTSD). NCT03039231. Published online March 25, 2020.
link